The EPC Enrichment and Enumeration Kit is designed for the enumeration of circulating EPCs (cEPCs) from peripheral blood, cord blood, or leukapheresis products as well as EPCs from bone marrow. To ensure reliable enumeration results, the EPCs are enriched during the procedure to increase the sensitivity of the flow cytometric analysis.
The kit contains all reagents for:
  • red blood cell lysis,
  • EPC enrichment,
  • blocking of Fc receptor–mediated non-specific labeling of non-target cells,
  • enumeration of EPCs based on expression of CD34, CD133, and

Data and images for EPC Enrichment and Enumeration Kit, human

Figures

Figure 1

View details
Identification of CD34
+
cells and CD133 specificity. Leukocytes after discrimination of debris and platelets and exclusion of dead cells and monocytes are shown. Cells were stained with CD34-FITC and Mouse IgG2b-PE representing the isotype control for CD133 staining. Cells were analyzed by flow cytometry.

Figure 1

Identification of CD34
+
cells and CD133 specificity. Leukocytes after discrimination of debris and platelets and exclusion of dead cells and monocytes are shown. Cells were stained with CD34-FITC and Mouse IgG2b-PE representing the isotype control for CD133 staining. Cells were analyzed by flow cytometry.

Figure 2

View details
Identification of CD34
+
CD133
+
cells in the pre-enriched EPC sample. Leukocytes after discrimination of cell debris and platelets and exclusion of dead cells and monocytes are shown. Cells were stained with CD34-FITC and CD133/2 (293C3)-PE and analyzed by flow cytometry. The population in R4 was used for further analysis of CD133 and CD309 expression shown in figures 3 and 4.

Figure 2

Identification of CD34
+
CD133
+
cells in the pre-enriched EPC sample. Leukocytes after discrimination of cell debris and platelets and exclusion of dead cells and monocytes are shown. Cells were stained with CD34-FITC and CD133/2 (293C3)-PE and analyzed by flow cytometry. The population in R4 was used for further analysis of CD133 and CD309 expression shown in figures 3 and 4.

Figure 3

View details
Enumeration of CD34
+
CD133
+
CD309 (VEGFR-2/KDR)
+
EPCs in the pre-enriched EPC sample. Leukocytes after discrimination of debris and platelets, exclusion of dead cells and monocytes are shown. Additionally, data were gated on CD34
+
cells. Cells were stained with CD309 (VEGFR-2/KDR)-APC and CD133/2 (293C3)-PE and analyzed by flow cytometry.

Figure 3

Enumeration of CD34
+
CD133
+
CD309 (VEGFR-2/KDR)
+
EPCs in the pre-enriched EPC sample. Leukocytes after discrimination of debris and platelets, exclusion of dead cells and monocytes are shown. Additionally, data were gated on CD34
+
cells. Cells were stained with CD309 (VEGFR-2/KDR)-APC and CD133/2 (293C3)-PE and analyzed by flow cytometry.

Figure 4

View details
Isotype control of CD309 staining in the pre-enriched EPC sample. Leukocytes after discrimination of debris and platelets, exclusion of dead cells and monocytes are shown. Additionally, data were gated on CD34
+
cells. Cells were stained with CD133/2 (293C3)-PE and Mouse IgG1-APC representing the isotype control for CD309 (VEGFR-2/KDR) staining. Cells were analyzed by flow cytometry.

Figure 4

Isotype control of CD309 staining in the pre-enriched EPC sample. Leukocytes after discrimination of debris and platelets, exclusion of dead cells and monocytes are shown. Additionally, data were gated on CD34
+
cells. Cells were stained with CD133/2 (293C3)-PE and Mouse IgG1-APC representing the isotype control for CD309 (VEGFR-2/KDR) staining. Cells were analyzed by flow cytometry.

Specifications for EPC Enrichment and Enumeration Kit, human

Overview

The EPC Enrichment and Enumeration Kit is designed for the enumeration of circulating EPCs (cEPCs) from peripheral blood, cord blood, or leukapheresis products as well as EPCs from bone marrow. To ensure reliable enumeration results, the EPCs are enriched during the procedure to increase the sensitivity of the flow cytometric analysis.
The kit contains all reagents for:
  • red blood cell lysis,
  • EPC enrichment,
  • blocking of Fc receptor–mediated non-specific labeling of non-target cells,
  • enumeration of EPCs based on expression of CD34, CD133, and CD309,
  • exclusion of CD14+ cells,
  • exclusion of dead cells,
  • isotype controls.

Detailed product information

Background information

Endothelial progenitor cells (EPCs) are defined by the expression of CD34, CD133, and CD309 (VEGFR-2/KDR)
1,2
and have been enumerated based on the expression of these markers by several studies. They are considered a measurable parameter for the assessment of risk factors for various diseases
3–5
as well as for the capacity for vascular repairing. cEPC numbers were correlated with, for example,
  • certain phases during congestive heart failure6,
  • acute myocardial infarction7,
  • risk factors for atherosclerosis5,
  • risk factors for cardiovascular disease8,
  • physical training9,
  • cessation of smoking10.
The EPC Enrichment and Eunmeration Kit contains everything needed for EPC enrichment followed by enumeration with CD34, CD133/2, CD309, CD14 fluorochrome-conjugated monoclonal antibodies.

Columns

MS or MACSQuant
®
Columns.

References for EPC Enrichment and Enumeration Kit, human

Publications

  1. Peichev, M. et al. (2000)
    Expression of VEGFR-2 and AC133 by circulating human CD34
    +
    cells identifies a population of functional endothelial precursors.
    Blood 95: 952-958
  2. Rafii, S. and Lyden, D. (2003) Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 9: 702-712
  3. Hill, J. et al. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348: 593-600
  4. Urbich, C. and Dimmeler, S. (2005) Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int. 67: 1672-1676
  5. Werner, N. and Nickenig, G. (2006) Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? Arterioscler. Thromb. Vasc. Biol. 26: 257-266
  6. Valgimigli, M. et al. (2004)
    CD34
    +
    and endothelial progenitor cells in patients with various degrees of congestive heart failure.
    Circulation 110: 1209-1212
  7. Massa, M. et al. (2005) Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 105: 199-206
  8. Vasa, M. et al. (2001) Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89: e1-e7
  9. Steiner, S. et al. (2005) Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. Atherosclerosis 181: 305-310
  10. Kondo, T. et al. (2004) Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler. Thromb. Vasc. Biol. 24: 1442-1447

Related products for
EPC Enrichment and Enumeration Kit, human

7 products available | view all

Seems like you are coming from USA!
Do you want to visit our website in your country?